NEW YORK, April 18, 2017 /PRNewswire/ --
For today, Stock-Callers.com covers the global Generic Drugs industry, whichhas grown strongly over the years, owing partly to the fact that the period for patent protection has gotten shorter with major blockbuster drugs losing their patent protection. Under assessment this morning are: Innocoll Holdings PLC (NASDAQ: INNL),
Athlone, Ireland headquartered Innocoll Holdings PLC's stock finished Monday's session 0.25% lower at $1.99 with a total trading volume of 379,422 shares. Over the last month and the previous three months, the Company's shares have advanced 5.99% and 226.18%, respectively. Additionally, the stock has surged 188.41% since the start of this year. The Company's shares are trading above their 50-day moving average by 85.94%. Moreover, shares of Innocoll Holdings, which manufactures and sells collagen-based pharmaceutical products and devices in Europe, Middle East, Asia, and the US, have a Relative Strength Index (RSI) of 65.73.
On March 29th, 2017, research firm JMP Securities resumed its 'Market Outperform' rating on the Company's stock.
On April 04th, 2017, Innocoll Holdings and Gurnet Point L.P. announced that they have reached an agreement on the terms of a recommended offer. Under the recommended offer, Gurnet Point will acquire Innocoll for $1.75 per share in cash, and up to $4.90 in cash from a contingent value right, for a total potential per share value of up to $6.65, or up to approximately $209 million in aggregate. Your complete research report on INNL can be retrieved for free at:
Shares in Coral Gables, Florida-based Catalyst Pharmaceuticals Inc. declined 2.84%, ending yesterday's session at $1.71 with a total trading volume of 242,861 shares. The stock has gained 13.25% in the past month, 37.90% in the previous three months, and 62.86% on an YTD basis. The Company's shares are trading 21.19% above their 50-day moving average and 51.31% above their 200-day moving average. Moreover, shares of Catalyst Pharma, which focuses on the development and commercialization of therapies for people with rare debilitating diseases, have an RSI of 53.89. A free report on CPRX is just a click away at: http://stock-callers.com/registration/?symbol=CPRX
On Monday, Norcross, Georgia-based Galectin Therapeutics Inc.'s stock saw a drop of 2.22%, to close the day at $3.09. A total volume of 602,211 shares was traded. The Company's shares have advanced 45.07% in the last one month, 171.05% in the previous three months, and 215.31% on an YTD basis. The stock is trading 60.14% above its 50-day moving average and 112.51% above its 200-day moving average. Additionally, shares of Galectin Therapeutics, which engages in the research and development of therapies for fibrotic disease and cancer, have an RSI of 69.86.
On March 28th, 2017, Galectin Therapeutics reported financial results for the year ended December 31st, 2016. For the full year 2016, net loss applicable to common stockholders was $22.4 million, R&D expense was $15.3 million, and general and administrative expense was $6.2 million. As of December 31st, 2016, the Company had $15.4 million of non-restricted cash and cash equivalents.
On March 30th, 2017, research firm H.C. Wainwright upgraded the Company's stock rating from 'Neutral' to 'Buy', with a target price of $3.50 per share. Sign up for your complimentary research report on GALT at:
Shares in Watertown, Massachusetts headquartered Tetraphase Pharmaceuticals Inc. ended the day 0.24% higher at $8.19. A total volume of 229,862 shares was traded. The stock has gained 4.07% in the last one month, 83.22% in the previous three months, and 103.23% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 21.87% and 74.76%, respectively. Furthermore, shares of Tetraphase Pharma, which develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections, have an RSI of 55.62.
On March 30th, 2017, Tetraphase Pharma announced that its pipeline candidate TP-6076 was selected to receive $4 million in research funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, an international, public-private partnership. In preclinical research, TP-6076 has demonstrated potent activity against MDR bacteria, particularly those considered to be urgent or serious threats by the US Centers for Disease Control and Prevention and the World Health Organization. Register for free on Stock-Callers.com and download the latest research report on TTPH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Parkinson's disease (PD) is a chronic and progressive disease of the nervous system, causing ...
Iridectomy is a procedure in which an opening is made in the iris of the eye.
Hand hygiene is a simple and affordable technique to prevent infections.View All